conversion to Ultomiris across indications, demand, offset by order timing in certain 2020 to 2025, calculated on a pro forma basis with 2021 and 2022 growth ca medicines have launched and have sales Collaboration partners: BridgeBio (Beyonttra), Merck & Co., Inc. (Koselugo) asset acquired in August 2025.